ArticleOncotarget2015

The PI3K inhibitor GDC-0941 displays promising in vitro and in vivo efficacy for targeted medulloblastoma therapy.

Michael Ehrhardt et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.